Reference Investigator Investigator's Title/Role Title Of .
Page 1 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked ID[Updated at least annually and within sixty (60) calendar days of the University’s identification of a new Financial Conflict of Interest]Description of ConflictRemuneration RemunerationRemuneration Amount EquityNameMulti-Tracer PET Assessment of PrimaryThe investigator's licensed intellectual property will be used in noyesBrain Tumorsthe study. The nvestigator has significant financial interest inthe licensing company.A Clinical Evaluation of the Vanguard XPThe investigator has a significant financial interest in Biomet, yesBiomet 5,000-9,999noBicruciate Knee System Early Intraoperative the study sponsor.& Candidacy AssessmentVanguard SSK 360 Revision Knee SystemThe investigator has a significant financial interest in Biomet, yesBiomet 5,000-9,999noGlobal Data Collectionthe study sponsor.Preliminary investigation of erectile function The investigator has an equity interest in Andro360, thenoyesusing a non-invasive measurement device company whose device will be evaluated in this study.Linked TitleCRV 00004729 Dan KadrmasCo-InvestigatorIRB 00031335CRV 00007427 Christopher PeltPrincipalInvestigator10032753CRV 00010944 Christopher PeltCo-InvestigatorIRB 00062862CRV 00012418 James HotalingCo-InvestigatorIRB 00073305CRV 00013955 Anne BlaschkeCo-InvestigatorIRB 00049682Molecular Classification of Pediatric CancerCRV 00013956 Anne BlaschkeCo-InvestigatorIRB 00042895CRV 00013963 Anne BlaschkeCo-InvestigatorIRB 00047322CRV 00014487 Christopher PeltCo-InvestigatorIRB 00075446CRV 00018821 Raminder NirulaPrincipalInvestigatorIRB 00074395CRV 00022076 Jayant AgarwalCo-InvestigatorIRB 00063220CRV 00022085 James BeckCo-InvestigatorIRB 00063220CRV 00022401 Anne BlaschkePrincipalInvestigator10035912CRV 00023217 Michael KayPrincipalInvestigator10035362CRV 00023765 cheryl wrightCo-InvestigatorIRB 00082197CRV 00024913 Jayant AgarwalCo-InvestigatorIRB 00082763CRV 00024914 James BeckCo-InvestigatorIRB 00082763CRV 00025488 James BeckPrincipalInvestigatorCo-InvestigatorIRB 00073178Co-InvestigatorIRB 00073178Co-Investigator10037171PARAPNEUMONIC EMPYEMA: USE OFMOLECULAR METHODS TO IDENTIFYPATHOGENS AND OUTCOMEMolecular Evaluation of Pediatric Joint Fluid The investigator's licensed intellectual property is being usedin the study.Clinical and Biomechanical OutcomesThe investigator has a financial interest in Biomet, which hasFollowing Total Knee Arthroplastyproducts being used in the study.Patient Driven Surgical Discharge ProcessThe investigator's intellectual property will be evaluated inImprovementthe study. The investigator has an equity interest in ProMD,which holds the license to the intellectual property.Pre-Screening and Screening to identify the The investigator has licensed intellectual property that will beVA (and/or military) population that meets evaluated in this study. The investigator has a financialmedical criteria for advanced prostheticinterest in the company, DJO Surgical, that has licensed thedevicestechnology.Pre-Screening and Screening to identify the The investigator has intellectual property that will beVA (and/or military) population that meets evaluated in the study.medical criteria for advanced prostheticdevicesFilmArray Direct: Rapid Diagnosis ofThe investigator's licensed intellectual property will beAntimicrobial-Resistant Pathogens fromevaluated in this study.BloodProtease-Resistant D-peptide Inhibitors ofThe investigator has a significant financial interest in Navigen,Ebola Entrythe study sponsor. The investigator's licensed intellectualproperty will be evaluated in the study.The Evaluation of a Peer-TeachingThe investigator's licensed intellectual property will be used inTechnology Education Program for Youth on the study. The nvestigator has significant financial interest inthe Autism Spectrumthe licensing company.Safety Study of PercutaneousThe investigator's licensed intellectual property will be used inOsseointegrated Implants for Prostheticthe study. The nvestigator has significant financial interest inAttachmentthe licensing company.Safety Study of PercutaneousThe investigator's intellectual property, which is licensed toOsseointegrated Implants for ProstheticDJO Surgical, will be evaluted in the study.AttachmentMicrobiome and Innate Immunity withThe investigator's licensed intellectual property may bePercutaneous Osseointegrated Prostheses evaluated in the study.Microbiome and Innate Immunity withThe investigator's licensed intellectual property will bePercutaneous Osseointegrated Prostheses evaluated in the study.Microbiome and Innate Immunity withThe investigator's licensed intellectual property will bePercutaneous Osseointegrated Prostheses evaluated in the study.Drug-Free Macromolecular TherapeuticsThe investigator's licensed intellectual property will beevaluated in the study.CRV 00025489 Jayant AgarwalCRV 00025491 SujeeviniJeyapalinaCRV 00026206 jiyuan YangIRB 00073178Equity NameEquity ValueIPIntellectual Property ValueMultiFunctionalImaging, LLCValue cannot be readilydeterminedyesValue cannot be readilydeterminednonoAndro360Value cannot be readilydeterminednoThe investigator's licensed intellectual property is being used noin the study.The investigator's licensed intellectual property is being used noin the study.noyesnoyesnonoyesnonoyesBiomet 10,000-19,999noValue cannot be readilydeterminednoyesValue cannot be readilydeterminednonoyesValue cannot be readilydeterminednonoyesValue cannot be readilydeterminednoyesNavigenValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesNeuroVersityValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesValue cannot be readilydeterminednonoyesValue cannot be readilydeterminednonoyesnonoyesnonoyesnonoyesValue cannot be readilydeterminedValue cannot be readilydeterminedValue cannot be readilydeterminedValue cannot be readilydeterminedyesDJO SurgicalDJO Surgical 10,000-19,999 10,000-19,999ProMDValue cannot be readilydeterminedValue cannot be readilydeterminedyesyesyesValue cannot be readilydeterminedValue cannot be readilydetermined
Page 2 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked IDLinked TitleCRV 00026207 Paul ShamiCo-Investigator10037171Drug-Free Macromolecular TherapeuticsCRV 00026247 Jindrich 0037171Drug-Free Macromolecular TherapeuticsIRB 00087108A Comparison of Two Surgical Methods ofManagement for Perthes DiseaseCRV 00033059 Loren RiethCo-InvestigatorIRB 00055621CRV 00036664 Anne BlaschkeCo-InvestigatorIRB 00089825CRV 00037314 Ken JohnsonCo-InvestigatorIRB 00090093Can an array of micro-electrodes implantedin a human nerve record neural signals andprovide sensory feedback useful forcontrolling a prosthetic device?FilmArray Direct: Rapid Diagnosis ofAntimicrobial-Resistant Pathogens fromBloodComparison of Effect Site Concentrations ofAnesthetic Agents with ProcessedElectroencephalographyCRV 00039373 Anne BlaschkeCo-Investigator10039921Sepsis Direct grantCRV 00040825 Jeremy GilillandPrincipalInvestigatorIRB 00091705Fluoroscopic Grid use in Total HipArthroplastyCRV 00041829 Christopher PeltCo-InvestigatorIRB 00089804CRV 00045640 Thomas HigginsLaboratoryTechnicianIRB 00089189CRV 00047963 Himanshu 3133CRV 00048955 Mark YandellCo-InvestigatorIRB 00088405Evaluation of serum metal ion levels in aseries of patients undergoing primary orrevision total hip arthroplasty with the G7Dual Mobility Construct"What happens on the back table? Viabilityand Osteogenic Potential of RIA bone graftas a function of time and temperature."A Biodegradable Vascular Coupling Devicefor End-to-End AnastomosisDevelopment of an integrated array forsimultaneous optical stimulation andelectrical recording for the study of corticalcircuit function in the nonhuman primatebrainGENETIC EPIDEMIOLOGY OFHEMATOLOGICAL MALIGNANCIESCRV 00049463 Gabor MarthCo-InvestigatorIRB 00065564Utah Genome ProjectCRV 00049575 Gregory ClarkCo-InvestigatorIRB 00055621Can an array of micro-electrodes implantedin a human nerve record neural signals andprovide sensory feedback useful forcontrolling a prosthetic device?CRV 00032407 Peter StevensCRV 00048355 Loren Rieth10041726[Updated at least annually and within sixty (60) calendar days of the University’s identification of a new Financial Conflict of Interest]Description of ConflictRemuneration RemunerationRemuneration Amount EquityNameThe investigator has an equity interest in Bastion Biologics,noyesthe company that holds the license on the technology beingstudied.The investigator's licensed intellectual property will benonoevaluated in the study.The investigator's intellectual property will be evaluated inyesOrthofix, Inc 10,000-19,999nothe study. The intellectual property is licensed to Orthofix, Inc,with which the investigator has a consulting relationship.The investigator is an employee of Blackrock Microsystems,whose licensed technology is being evaluated in this study.yesThe investigator's licensed intellectual property will beevaluated in the study.IPBastion BiologicsValue cannot be readilydeterminednoyesyesIntellectual Property ValueValue cannot be readilydeterminedValue cannot be readilydeterminednononoyesValue cannot be readilydeterminedThe investigator has licensed intellectual property that will beevaluated in the study. The investigator has an equityinterest in Medical Visualizations, which holds the license tothe intellectual property.The investigator's licensed intellectual property will beevaluated in the study.The investigator has an equity interest in OrthoGridTechnologies, whose technology is being evaluated in thestudy. The investigator also discloses he is a co-inventor ofthe technology.The investigator has a significant financial interest in thestudy sponsor Biomet.noyesyesValue cannot be readilydeterminednonoyesnoyesValue cannot be readilydeterminedValue cannot be readilydeterminedyesBiomet 5,000-9,999nonoThe investigator has a significant financial interest in DePuySynthes, whose RIA bone graft is the focus of the study.yesDepuy Sythes 10,000-19,999nonoThe investigator has an equity interest in MicrosurgicalInnovations.The investigator has a significant financial interest inBlackrock Microsystems. Blackrock LED array drivers will beused in the study.noThe investigator's licensed intellectual property will be used in yesthe research. The investigator has a significant financialinterest in the licensing company.The investigator’s intellectual property is being used in thenoresearch, and is exclusively licensed to Frameshift Labs (a nonpublicly company in which the investigator has significantequity interest).The investigator's licensed intellectual property will be used in nothe study. 20,000-39,999Equity ValuenoyesBlackrockMicrosystemsEquity NameyesBlackrockMicrosystems 20,000-39,999Fabric Genomics 80,001 to 99,999formerly known MicrosurgicalInnovationsValue cannot be readilydeterminedValue cannot be readilydeterminedValue cannot be readilydeterminednoyesyesnoyesnonoFabric Genomicsformerly known asOmiciaFrameshift LabsValue cannot be readilydeterminedyesValue cannot be readilydeterminedValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydetermined
Page 3 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked IDCRV 00050595 Robert SchlabergCo-InvestigatorIRB 00097639CRV 00051773 Aaron QuinlanCo-InvestigatorIRB 00044244CRV 00052162 Jeremy GilillandPrincipalInvestigatorIRB 00098977CRV 00052546 Robert SchlabergPrincipalInvestigatorIRB 00099611CRV 00053450 David WarrenPrincipalInvestigatorIRB 00055621CRV 00055132 Aaron QuinlanCo-Investigator10042615CRV 00055376 Paul r10042831CRV 00055929 K-T VARLEYPrincipalInvestigator10039059CRV 00056856 Sean RunnelsPrincipalInvestigatorIRB 00090403CRV 00057481 Eric SchmidtPrincipalInvestigator10042382CRV 00059352 James HotalingCo-InvestigatorIRB 00072148CRV 00060157 Gabor MarthPrincipalInvestigatorIRB 00103793CRV 00060690 Zachary ImelPrincipalInvestigator10041107CRV 00055402 Aaron Quinlan10040371[Updated at least annually and within sixty (60) calendar days of the University’s identification of a new Financial Conflict of Interest]Description of ConflictRemuneration RemunerationRemuneration Amount EquityNameMetagenomic approach to the evaluation of The investigator's intellectual property will be used in study. It noyesmyocarditishas been licensed to IDbyDNA, a non-publicly tradedcompany in which the investigator has significant equityinterest as founder.Genetic risk factors in suicide and depression The investigator's intellectual property will be used in thenoyesresearch. This intellectual property is exclusively licensed toBase2 Genomics, a company in which the investigator has asignificant equity interest.Intraoperative Data Collection for the use of The investigator has a significant interest in OrthoGrid, thenoyesa Novel Digital Fluoroscopic Gridstudy sponsor and manufacturer of the investigational deviceused in the study.Reproducibility of pathogen detection byThe investigator's intellectual property, Taxonomer, will benoyesmetagenomicsused in study. It has been licensed to IDbyDNA, a non-publiclytraded company in which the investigator has significantequity interest as founder.Can an array of micro-electrodes implanted The investigator's licensed intellectual property will be used in nonoin a human nerve record neural signals and the study.provide sensory feedback useful forcontrolling a prosthetic device?Novel DNA damage response gene fromThe investigator's intellectual property will be used in thenoyesgenomic screeningresearch. It is exclusively licensed to Base2 Genomics, acompany in which the investigator has a significant equityinterest.Biochemistry and Pharmacology of theThe investigator's licensed intellectual property will be used in nonoMacular Carotenoidsthe research.Computational tools for monitoring tumorThe investigator's intellectual property will be used in thenoyesheterogeneity over time and spaceresearch. The intellectual property is licensed to Base2Genomics, a company in which the investigator has asignificant equity interest.A partnership to enable clinical ctDNA testing The investigator has significant financial interestsyesKailos Genetics 20,000-39,999yesfor breast cancer recurrence(employment remuneration and equity interest) in KailosGenetics, a non-publicly traded company that will partner withthe Varley Lab at University of Utah to conduct this research.The investigator reports her intellectual property will bedeveloped and used in this study.Airway exchange catheter tip control in the The investigator has a significant interest in "Through thenoyestrachea with and without videolaryngoscopy cords, LLC," a non-publicly traded company whose technologyin airway mannequinsis being evaluated in the study.Symbiosis and Chemical DiversityThe investigator's licensed intellectual property will be used in noyesGenerationthe study. The intellectual properties are licensed to SyntheticBiodesign, a non-publicly traded company in which theinvestigator has a significant equity interest.Validation study of urine flow rateThe investigator's intellectual property is being used in thenoyesmonitoring with novel device: StreamDx.study. It has been exclusively licensed to StreamDX, a nonpublicly traded company in which the investigator hassignificant equity interest.Web tools to enhance physician-drivenThe investigator's intellectual property will be evaluated innoyesdiagnostic interpretation of genomic patient the research, and has been exclusively licensed to FrameshiftdataLabs (a non-publicly traded company in which the investigatorhas significant equity interest).Implementation of Technology-basedThe investigator's intellectual property is being used in thenoyesEvaluation of Motivational Interviewingresearch. The investigator reports an equity interest inLyssn.io, which will be commercializing the intellectualproperty.Linked TitleEquity NameEquity ValueIPIntellectual Property ValueIDbyDNAValue cannot be readilydeterminedyesValue cannot be readilydeterminedBase2GenomicsValue cannot be readilydeterminedyesValue cannot be readilydeterminedOrthoGridValue cannot be readilydeterminednoIDbyDNAValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydeterminedValue cannot be readilydeterminedBase2GenomicsValue cannot be readilydeterminedBase2GenomicsValue cannot be readilydeterminedyesKailos GeneticsValue cannot be readilydeterminedyesThrough the cordsValue cannot be readilydeterminednoValue cannot be readilydeterminedSynthetic Biodesign Value cannot be readilydeterminedyesValue cannot be readilydeterminedStreamDXValue cannot be readilydeterminedyesValue cannot be readilydeterminedFrameshift LabsValue cannot be readilydeterminedyesValue cannot be readilydeterminedLyssn.ioValue cannot be readilydeterminedyesValue cannot be readilydetermined
Page 4 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked IDCRV 00060831 Jutta DeiningerCo-InvestigatorIRB 00099894CRV 00060893 Mark YandellCo-Investigator10043756CRV 00061132 Gabor MarthPrincipalInvestigator10042890CRV 00061310 Aaron QuinlanCo-Investigator10042890CRV 00061317 Aaron QuinlanPrincipalInvestigator10043756CRV 00061323 Aaron QuinlanCo-InvestigatorIRB 00095233CRV 00061593 James HotalingPrincipalInvestigator10043586CRV 00061627 Jutta DeiningerCo-InvestigatorIRB 00088099CRV 00062058 Eugene Kholmovski Co-Investigator10041434CRV 00062071 Mark YandellCo-Investigator10044535CRV 00062080 Michael TananaData AnalystIRB 00083132CRV 00062081 Zachary ImelPrincipalInvestigatorIRB 00083132CRV 00062097 Gabor MarthPrincipalInvestigator10043785Linked Title[Updated at least annually and within sixty (60) calendar days of the University’s identification of a new Financial Conflict of Interest]Description of ConflictRemuneration RemunerationRemuneration Amount EquityNameThe investigator's spouse has a significant financial interest in yesPfizer 10,000-19,999noPfizer, whose drug Palbociclib is being evaluated in the study.Alliance Foundation Trials AFT-38 ARandomized, Open Label, Phase III Trial toEvaluate the Efficacy and Safety ofPalbociclib Anti-HER2 Therapy EndocrineTherapy vs. Anti-HER2 Therapy EndocrineTherapy after Induction Treatment forHormone ReceptSoftware for exploring all forms of geneticThe investigator's licensed intellectual property will be used invariation in any speciesthe research. The investigator has a significant financialinterest in the licensing company.IOBIO: Web-based, interactive tools for real- The investigator's intellectual property will be used in thetime analysis in genomic big dataresearch, and has been exclusively licensed to FrameshiftLabs (a company in which the investigator has a significantequity interest).IOBIO: Web-based, interactive tools for real- The investigator's licensed intellectual property will be used intime analysis in genomic big datathe study. The nvestigator has significant financial interest inthe licensing company.Software for exploring all forms of geneticThe investigator's intellectual property will be used in thevariation in any speciesresearch. It is exclusively licensed to Base2 Genomics, acompany in which the investigator has a significant equityinterest.The genetic basis of hypersensitivity toThe investigator's intellectual property will be used in theionizing radiationresearch. It is exclusively licensed to Base2 Genomics, acompany in which the investigator has a significant equityinterest.Stream Dx: accurate and efficient, point-of- The investigator's intellectual property is being used in thecare uroflometry for improved diagnosis,study. It has been exclusively licensed to StreamDX, a nonmonitoring, and post-treatment evaluation publicly traded company in which the investigator has aof LUTSsignificant equity interest.Alliance Foundation Trials AFT – 05 The investigator reports significant spousal remunerationPALLAS: PALbociclib CoLlaborative Adjuvant from study sponsor Pfizer.Study: A randomized phase III trial ofPalbociclib with standard adjuvant endocrinetherapy versus standard adjuvant endocrinetherapy alone for hormone receptor positive(New 3D and 4D Image-Based ClinicalThe investigator's intellectual property will be used in theMeasures of Atrial Structural and Functional study. It has been exclusively licensed to Marrek, a nonRemodeling in Atrial Fibrillationpublicly traded company in which the investigator has asignificant equity interest.The Genetics of Primary OvarianThe investigator's licensed intellectual property will be used inInsufficiencythe research. The investigator has a significant financialinterest in the licensing company.Implementation of Technology-BasedThe investigator has a significant equity interest in Lyssn.io, aEvaluation of Motivational Interviewingnon-publicly traded company which will be commercializingthe intellectual property used in the study.Implementation of Technology-BasedThe investigator's intellectual property is being used in theEvaluation of Motivational Interviewingresearch. The investigator reports a significant equity interestin Lyssn.io, a non-publicly traded company which will becommercializing the intellectual property.Web tools for physician-driven diagnosticThe investigator's intellectual property will be evaluated ininterpretation of genomic patient datathe research. The intellectual property is licensed toFrameshift Labs, a non-publicly traded company in which theinvestigator has a significant equity interest.yesIPIntellectual Property ValuenonoyesnoyesBase2 GenomicsValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesBase2 GenomicsValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesBase2 GenomicsValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesStreamDxValue cannot be readilydeterminedyesValue cannot be readilydeterminedPfizer 10,000-19,999noyesFabric Genomics 80,001 to 99,999formerly known asOmiciayesEquity ValueFabric Genomicsformerly known asOmiciaFrameshift LabsyesFabric Genomics 80,001 to 99,999formerly known asOmiciaEquity NameValue cannot be readilydeterminedyesValue cannot be readilydeterminedValue cannot be readilydeterminedyesValue cannot be readilydeterminednonoyesMarrek, IncValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydeterminedyesValue cannot be readilydeterminedValue cannot be readilydeterminednonoyesFabric Genomicsformerly known asOmiciaLyssn.ionoyesLyssn.ioValue cannot be readilydeterminedyesValue cannot be readilydeterminednoyesFrameshift LabsValue cannot be readilydeterminedyesValue cannot be readilydetermined
Page 5 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked IDCRV 00063164 Michael KayCo-Investigator10044932CRV 00063601 Gabor MarthPrincipalInvestigator10043494CRV 00063610 Lucinda BatemanCo-InvestigatorIRB 00098946CRV 00063779 Gabor MarthPrincipalInvestigator10044794CRV 00063833 Kerry KellyPrincipalInvestigator10042257CRV 00063837 Kerry KellyPrincipalInvestigatorIRB 00091794CRV 00064098 Stephen Summers PrincipalInvestigator10043586CRV 00064292 Scott SummersCo-Investigator10043577CRV 00064808 Robert SchlabergCo-InvestigatorIRB 00103100CRV 00064888 Aaron QuinlanPrincipalInvestigator10042735CRV 00065014 Brook MartinPrincipalInvestigator10045701CRV 00065016 Brook MartinPrincipalInvestigatorIRB 00099871[Updated at least annually and within sixty (60) calendar days of the University’s identification of a new Financial Conflict of Interest]Description of ConflictRemuneration RemunerationRemuneration Amount EquityNameCenter for the Structural Biology of Cellular The investigator's intellectual property will be used in theyesNavigen 10,000-19,999yesHost Elements in Egress, Trafficking, andresearch. Commercialization may be imminent throughAssembly of HIV (CHEETAH Center)Navigen, a company in which the investigator has significantequity interest and consulting remuneration.Visually-driven disease variant analysisThe investigator's intellectual property will be evaluated innoyesempowering real-time clinical researchthe research, and has been exclusively licensed to FrameshiftLabs (a non-publicly traded company in which the investigatorhas a significant equity interest).Using the UPDB to Increase Understanding The investigator has a significant financial interest in Bateman yesBateman Home 80,000- 99,999noof Chronic Fatigue Syndrome andHorne Center of Excellence, where electronic records will beHealth Center forFibromyalgiaobtained from in the study.ExcellenceNovel iobio analysis supporting genomeThe investigator's intellectual property will be evaluated innoyesscale data quality controlthe research, and has been exclusively licensed to FrameshiftLabs (a non-publicly traded company in which the investigatorhas significant equity interest).AirU: Community Network to Understand Air The investigator's intellectual property is being used in thenoyesQuality and Sensor Reliabilitystudy, and commercialization may be imminent throughTetrad: Sensor Network Solutions (a company in which theinvestigator has significant equity interest).Air Quality Web Site and Teaching Module The investigator's intellectual property is being used in thenoyesUse by Citizen Scientistsstudy, and commercialization may be imminent throughTetrad: Sensor Network Solutions (a company in which theinvestigator has significant equity interest).Stream Dx: accurate and efficient, point-of- The investigator reports significant equity interest innoyescare uroflometry for improved diagnosis,StreamDx, the study sponsor.monitoring, and post-treatment evaluationof LUTSDihydroceramide Desaturase-1 Inhibitors for The investigator has a significant financial interest inyesCentaurus 10,000-19,999yesTreatment of Diabetes and Other Metabolic Centaurus Therapeutics, which is a subsidiary of the studyTherapeuticsDiseasessponsor Potrero Hill Therapeutics.Metagenomics Approach to the Evaluation The investigator's intellectual property will be used in theyesIDbyDNA 60,000-79. 999yesof Kawasaki Diseasestudy. It has been exclusively licensed to IDbyDNA, a nonpublicly traded company in which the investigator has asignificant equity interest.A powerful web-based discovery platformThe investigator's intellectual property will be used in thenoyesfor rare disease genomicsresearch. It is exclusively licensed to Base2 Genomics, acompany in which the investigator has a significant equityinterest.The Influence of an expanded bundledThe investigator reports significant equity interest in Statix,noyespayment program on patient-reportedLLC (formerly known as Gold Standard Research), a nonoutcomes, episode-of-care costs, procedure publicly traded company which was contracted for use of theirvolume, and safety.web-enabled content management system to help collectpatient-reported outcomes. Per investigator, secondaryanalysis of this data will be performed in this study.Linked TitleInfluence of an expanded mandatorybundled payment program on patientreported outcomes, episode-of-care costs,procedure volume, and safety.The investigator reports significant equity interest in Statix,noLLC (formerly known as Gold Standard Research), a nonpublicly traded company which was contracted for use of theirweb-enabled content management system to help collectpatient-reported outcomes. Per investigator, secondaryanalysis of this data will be performed in this study.yesEquity NameEquity ValueIPIntellectual Property ValueNavigenValue cannot be readilydeterminedyesValue cannot be readilydeterminedFrameshift LabsValue cannot be readilydeterminedyesValue cannot be readilydeterminednoFrameshift LabsValue cannot be readilydeterminedyesValue cannot be readilydeterminedTetrad: SensorsNetwork SolutionsValue cannot be readilydeterminedyesValue cannot be readilydeterminedTetrad: SensorsNetwork SolutionsValue cannot be readilydeterminedyesValue cannot be readilydeterminedStreamDxValue cannot be readilydeterminednoCentaurusTherapeuticsValue cannot be readilydeterminednoIDbyDNAValue cannot be readilydeterminedyesValue cannot be readilydeterminedBase2GenomicsValue cannot be readilydeterminedyesValue cannot be readilydeterminedStatix, LLCValue cannot be readilydeterminednoStatix, LLCValue cannot be readilydeterminedno
Page 6 of 27Individual Conflict of Interest Public Disclosures as of February 3, 2022IDDiscloserTitle and RoleLinked IDCRV 00066434 Kent BachusPrincipalInvestigator10045959CRV 00066439 Sean RunnelsPrincipalInvestigatorIRB 00095038CRV 00066629 Kent B 00011755CRV 00067455 Florian SolzbacherCo-Investigator10033446CRV 00068823 K-T VARLEYCo-InvestigatorIRB 00041211CRV 00069196 Robert BurksCo-InvestigatorIRB 00101394CRV 00069213 Mark YandellCo-Investigator10036978CRV 00069222 Mark YandellPrincipalInvestigator10027982CRV 00069223 Mark YandellCo-Investigator10038816CRV 00069226 Mark YandellCo-Investigator10036824CRV 00069227 Mark YandellCo-InvestigatorIRB 00084861CRV 00069229 Mark YandellCo-InvestigatorIRB 00066143CRV 00069233 Mark YandellCo-InvestigatorIRB 00021080CRV 00069235 Mark YandellCo-InvestigatorIRB 00006042CRV 00069236 Mark YandellCo-InvestigatorIRB 00065564CRV 00069474 Jeremy GilillandCo-InvestigatorIRB 00075446CRV 00066990 Kent BachusIRB 00065516Linked TitlePercutaneous Osseointegrated DockingSystem for Above Elbow Amputees.IPACastoleneTHE EFFECTS OF A UNIQUE COLOR ZONESYSTEM ON ENDOTRACHEAL TUBE DEPT
Vanguard XP Bicruciate Knee System: GK9b Biomet Income for Consulting 20,000-39,999 CRV_00012310 Christopher Pelt Associate Professor and Co- Investigator Randomized Controlled Clinical Outcomes of the
Title - Lender's Title Policy 535 Title - Settlement Agent Fee 502 Title - Title Search 1,261 Title - Lender's Title Insurance 1,100 Delta Title Inc. Frank Fields 321 Avenue D Anytown, ST 12321 frankf@deltatitle.com 222-444-6666 Title - Other Title Services 1,000 Title - Settlement Agent Fee 350
Independent Personal Pronouns Personal Pronouns in Hebrew Person, Gender, Number Singular Person, Gender, Number Plural 3ms (he, it) א ִוה 3mp (they) Sֵה ,הַָּ֫ ֵה 3fs (she, it) א O ה 3fp (they) Uֵה , הַָּ֫ ֵה 2ms (you) הָּ תַא2mp (you all) Sֶּ תַא 2fs (you) ְ תַא 2fp (you
Title Guarantee, a Title Insurance Agency, LLC - As your title contact of choice Title Guarantee, a Title Insurance Agency, LLC, is happy to provide you with a quick reference guidebook to help you through common title insurance principles. Title Guarantee was founded in 2011
vcu Office of the Vice President for Research and Innovation VCU/VCUHS NSR IDE Sponsor-Investigator Responsibilities . A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA . Code of Federal Regulations 21 CFR 812. This means th
Private Investigator (PI) 1. What are the licensing requirements for a Private Investigator? The general requirements for a Private Investigator are: Be at least 18 years old. Three years of compensated experience totaling not less than 6,000 hours in investigative work, while employed by law enforcement agencies, collection
The Louisiana State Board of Private Investigator Examiners set forth ethical standards for licensed private investigators in two main sources: Louisiana "Private Investigator Law" and Private Investigator Rules and Regulations. Both sources mentioned are available online in pdf format at the LSBPIE website (www.LSBPIE.com). a.
Number: PAR-03-108 Title: NIH SMALL RESEARCH GRANT PROGRAM (R03) 3. PRINCIPAL INVESTIGATOR/PROGRAM DIRECTOR New Investigator No Yes 3a. NAME (Last, first, middle) 3b. DEGREE(S) 3h. eRA Commons User Name Mithoefer, Michael C MD 3c. POSITION TITLE Psychiatrist, investigator 3e. DEPARTMENT, SERVICE, LABORATORY, OR EQUIVALENT Contractor
Agile software development therefore has a focus on: . Scrum is one of the most popular agile development methodologies. Scrum is a lightweight framework designed to help small, close-knit teams of people to create complex software products. The key features of the scrum methodology are as follows: Scrum team: A team of people using this methodology are called a “scrum”. Scrums usually .
